Compare SAFE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | CTMX |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 977.1M |
| IPO Year | 1999 | 2015 |
| Metric | SAFE | CTMX |
|---|---|---|
| Price | $14.96 | $3.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $19.00 | $12.10 |
| AVG Volume (30 Days) | 290.5K | ★ 3.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $385,552,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | $7.61 |
| P/E Ratio | $37.75 | ★ $22.58 |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $1.72 |
| 52 Week High | $17.16 | $8.21 |
| Indicator | SAFE | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 30.33 |
| Support Level | $14.70 | $3.06 |
| Resistance Level | $15.31 | $3.49 |
| Average True Range (ATR) | 0.35 | 0.18 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 70.40 | 11.26 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.